Rheumatology Daily Report: 01/22/2024

A Phase III Longitudinal Study investigated the effect of baricitinib in patients with active rheumatoid arthritis who had inadequate response to MTX, csDMARDs, or bDMARDs (1). The study included data from three completed phase III studies (RA-BEAM, RA-BUILD, RA-BEACON) and one long-term extension study (RA-BEYOND) analyzed up to 6.5 years. Low disease activity (LDA) was achieved in 37%/83% of MTX-IR, 35%/83% of csDMARD-IR, and 23%/73% of bDMARD-IR patients treated with baricitinib 4 mg, assessed by NRI/completer analyses, respectively. Remission was achieved in 20%/40% of MTX-IR, 13%/32% of csDMARD-IR, and 9%/30% of bDMARD-IR patients. HAQ-DI ≤0.5 was reached in 31%/51% of MTX-IR, 25%/46% of csDMARD-IR, and 24%/38% of bDMARD-IR patients.

 Reference

Caporali R, Taylor PC, Aletaha D, Sanmartí R, Takeuchi T, Mo D, Haladyj E, Bello N, Zaremba-Pechmann L, Fang Y, Dougados M. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study. Rheumatology (Oxford). 2024 Jan 22:keae012. doi: 10.1093/rheumatology/keae012. Epub ahead of print. PMID: 38258434.